THAL-SNS-032

Cat. No.: HY-123937

CAS No.: 2139287-33-3

Molecular Formula: $C_{40}H_{52}N_8O_{10}S_2$

Molecular Weight: 869.02

Target: PROTACs; CDK

Pathway: PROTAC; Cell Cycle/DNA Damage

Storage: -20°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (115.07 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.1507 mL	5.7536 mL	11.5072 mL
	5 mM	0.2301 mL	1.1507 mL	2.3014 mL
	10 mM	0.1151 mL	0.5754 mL	1.1507 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (2.88 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (2.88 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

THAL-SNS-032 is a selective CDK9 degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN)[1].

IC_{50} & Target

CDK9[1]

In Vitro

THAL-SNS-032 selectively induces degradation of CDK9[1].
THAL-SNS-032 diminishes elongating polymerase II[1].
THAL-SNS-032 inhibits proliferation of MOLT4 cells with an IC_{50} of 50 nM[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Mol Cell. 2021 Aug 31;S1097-2765(21)00646-8.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Olson CM, et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat Chem Biol. 2018 Feb;14(2):163-170.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA